Shenzhen Hepalink Pharmaceutical Group Co Ltd operates within the Medicinals and botanicals sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Shenzhen Hepalink Pharmaceutical Group Co Ltd with three other
companies in this sector in China:
Shandong Lukang Pharmaceutical
sales of 2.60 billion Chinese Renmimbi [US$379.57 million]
of which 68%
was Human Antibiotic),
Shandong Jincheng Pharmaceutical Group Co Ltd
(2.79 billion Chinese Renmimbi [US$407.14 million]
of which 72%
was Medicine Manufacturing), and
Yabao Pharmaceutical Group Company Limited
(2.56 billion Chinese Renmimbi [US$373.62 million]
of which 83%
was Pharrmaceutical Manufacturing).
During the year ended December of 2017, sales at
Shenzhen Hepalink Pharmaceutical Group Co Ltd were 2.67 billion Chinese Renmimbi (US$389.88 million).
increase of 18.2%
versus 2016, when the company's sales were 2.26 billion Chinese Renmimbi.
Sales of Other Operating saw an increase
that was more than double the company's growth rate: sales were up
70.2% in 2017, from
367,490.08 Chinese Renmimbi to 625,316.15 Chinese Renmimbi.